Table 2.
Clinical characteristics of the study cohorta.
| Deep brain simulation (DBS)bn = 17 | Levodopa-based pump therapycn = 15 | |||
|---|---|---|---|---|
| Patient | Close relative | Patient | Close relative | |
| Changes in motor symptoms following DAT d,e (n, %) | ||||
| Improvement | 8 (47.1) | 7 (41.2) | 10 (66.7) | 10 (66.7) |
| No change | 2 (11.8) | 4 (23.5) | 3 (20.0) | 3 (20.0) |
| Worsening | 7 (41.2) | 6 (35.3) | 2 (13.3) | 2 (13.3) |
| Changes in quality of life following DATf (n, %) | ||||
| Improvement | 7 (41.2) | 5 (29.4) | 12 (80) | 11 (73.3) |
| No change | 4 (23.5) | 5 (29.4) | 2 (13.3) | 1 (6.7) |
| Worsening | 6 (35.3) | 7 (41.2) | 1 (6.7) | 3 (20.0) |
aValues are reported as median and first and third quartiles (q1–q3) and numbers and percentages. 32 participants are included in total.
bDBS: Deep brain stimulation.
cLevodopa-based pump therapy: Levodopa–carbidopa intestinal gel with or without entacapone.
dDAT, Device-aided therapy, i.e., DBS or pump.
eChanges in motor symptoms, the patient's or close relative's perception of change in the patient's motor functioning following DAT (worse, same, and improvement).
fChanges in quality of life, the patient's or close relative's perception of change in the patient's quality of life following DAT (worse, same, and improvement).